10-K: SS Innovations International Reports Full Year 2023 Results, Revenue Growth Driven by SSi Mantra Sales

SS Innovations International reports a significant increase in revenue for 2023, driven by sales of its SSi Mantra surgical robotic system, while also highlighting ongoing efforts in research and development and regulatory approvals.

Summary

• SS Innovations International, Inc. reported a net loss of $20.9 million for the year ended December 31, 2023, compared to a net loss of $5.6 million in 2022.
• The company's revenue increased to $5.88 million in 2023, up from $1.46 million in 2022, primarily due to increased sales of the SSi Mantra surgical robotic system and related instruments.
• Research and development expenses rose to $576,168 in 2023, compared to $83,282 in 2022, reflecting the company's focus on product enhancement.
• Stock compensation expenses significantly increased to $13.4 million in 2023, up from $1.1 million in 2022, due to stock grants to employees and executive officers.
• The company installed 23 SSi Mantra systems by the end of 2023, with 21 in India, one in Dubai, and one at Johns Hopkins Hospital for training and research.
• As of December 31, 2023, the company had a total of 239 employees, with the majority based in India.
• The company is pursuing regulatory approvals in the United States and the European Union, with a pre-submission meeting scheduled with the FDA for April 2, 2024.
• The global surgical robotics market is projected to reach $37.5 billion by 2032, growing at a compound annual growth rate of 17.5% from 2023 to 2032.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth and market traction, the significant net loss, internal control weaknesses, and dependence on future capital raises temper the positive aspects. The company is in a high-growth phase but faces significant challenges.

Positives

• The company experienced substantial revenue growth in 2023, driven by increased sales of its SSi Mantra surgical robotic system.
• The company successfully installed 23 SSi Mantra systems by the end of 2023, demonstrating market traction.
• The company is actively pursuing regulatory approvals in key markets like the U.S. and Europe.
• The company has a strong focus on research and development, aiming to enhance its products and expand its offerings.
• The company has established strategic partnerships to expand its distribution network, including a memorandum of understanding with Surgical Lab, Ltd. for the African continent and an agreement in principle with Medikabazaar in India.

Negatives

• The company reported a significant net loss of $20.9 million for 2023, primarily due to increased stock compensation expenses.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to a lack of written documentation of internal control policies and insufficient segregation of duties.
• The company has a history of losses and may continue to incur losses for some time.
• The company is dependent on obtaining regulatory approvals in various regulated markets to sell its products.
• The company faces competition from established companies with greater financial resources.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company's reliance on sole-sourced or single-sourced suppliers for some components could lead to supply chain disruptions.
• The company faces risks related to intellectual property protection and potential infringement claims.
• The company's products are subject to extensive government regulations, and failure to comply could result in sanctions or fines.
• The company's success depends on continued clinical and technical innovation, quality, and reliability, as well as educating hospitals, surgeons, and patients on the benefits of its system.

Future Outlook

The company plans to expand its manufacturing capacity, continue research and development, and pursue regulatory approvals in the U.S. and Europe. They also intend to focus on underserved markets and key institutions to drive adoption of the SSi Mantra system.

Management Comments

• The company's vision is to create new, technologically advanced systems that will surpass existing surgical robotic systems to provide cost-effective surgical solutions to benefit greater numbers of patients around the world.
• The SSi Mantra was specifically developed from the ground up to address the issues of high costs and steep learning curves associated with existing surgical robotic systems.
• The company believes that the SSi Mantra system can significantly penetrate the Indian market, as well as other underserved markets in Asia, Africa, Europe, Central and South America and elsewhere.

Industry Context

The surgical robotics market is experiencing significant growth, with a projected CAGR of 17.5% from 2023 to 2032. SS Innovations is positioning itself to capitalize on this growth by offering a cost-effective alternative to existing systems, particularly in underserved markets.

Comparison to Industry Standards

• The SSi Mantra system is designed to be more affordable than existing systems, with a cost approximately one-third of competitors like Intuitive Surgical.
• The company is focusing on ease of training for surgeons, which is a key differentiator from other robotic surgery systems.
• The company's strategy of targeting underserved markets like India contrasts with the focus of many competitors on developed countries.
• The company's system has been clinically validated for safety, efficacy, and effectiveness in over fifty different types of surgical procedures in India, demonstrating its versatility.
• The company's system has been used in approximately 800 surgical procedures in India, indicating a growing adoption rate.

Corporate Governance

Legal Proceedings

• The company is currently evaluating its legal options with respect to a judgment against it in the amount of $296,000 plus interest from November 2020, related to a dispute with the law firm of Quinn Emmanuel Urquhart & Sullivan LLP.
• Mr. Cohen has agreed to fully indemnify the Company for any damages and costs it incurs in connection with the action.

Related Party Transactions

• The company had $1.47 million due from related parties as of December 31, 2023.
• The company executed a Convertible Promissory Note with Sushruta Pvt Ltd. for up to $20 million, which was fully converted into common stock.
• Dr. Sudhir Srivastava made interest-free demand loans to SSI-India.
• The company sold two surgical robotic systems to Aster Hospitals Group, where Dr. SP Somashekhar is a director.
• The company granted stock options to certain executive officers.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Employees may benefit from stock grants and the company's growth.
• Customers (hospitals and surgeons) will have access to a more affordable surgical robotic system.
• Patients may benefit from the minimally invasive procedures enabled by the SSi Mantra system.
• Suppliers may see increased business as the company expands its manufacturing capacity.

Next Steps

• The company will continue to pursue regulatory approvals in the U.S. and Europe.
• The company plans to expand its manufacturing capacity to meet anticipated demand.
• The company will continue to develop and enhance its technology and products.
• The company will focus on marketing the SSi Mantra to leading surgeons and key institutions.
• The company will continue to enter into agreements with major medical facilities for evaluation, familiarization, and training purposes.

Key Dates

Keywords

surgical robotics, SSi Mantra, robotic surgery, medical devices, healthcare, regulatory approvals, India, minimally invasive surgery, medical technology, surgical instruments